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CD40L = CD40 ligand; DC = dendritic cell; GM-CSF = granulocyte/macrophage colony-stimulating factor; HNSCC = head and neck squamous
cell carcinoma; IL = interleukin; PBMC = peripheral blood mononuclear cell; TNF = tumor necrosis factor.
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Abstract
Dendritic cells (DCs) are a complex network of antigen-
presenting cells that have an essential role in the modulation of
primary immunity. There has been increasing evidence that DCs
isolated from patients with malignancy demonstrate functional
deficiencies that inhibit the capacity to mount an effective anti-
tumor response. In this issue of Breast Cancer Research, Pinzon-
Charry and colleagues investigate one of the possible
mechanisms by which tumors induce DC dysfunction to evade
host immune surveillance. They demonstrate that DCs isolated
from the circulation of patients with early-stage breast cancer
exhibit increased rates of spontaneous apoptosis. In vitro studies
suggest that a soluble factor secreted by breast cancer cells is
responsible for this phenomenon. In contrast, ex vivo
conditioning of DCs with CD-40 ligand and IL-12 was protective
against tumor-induced apoptosis.
Dendritic cells (DCs) are the most potent antigen-presenting
cells and are uniquely capable of stimulating primary immune
responses by the presentation of antigen in the context of high
levels of costimulatory molecule expression [1,2]. The
functional characteristics of DCs evolve with their stage of
maturation. Immature DCs are found at sites of antigen
capture and excel at antigen processing, but lack significant
stimulatory capacity. After antigen uptake, DCs undergo
further differentiation characterized by the loss of phagocytic
capacity and increased expression of costimulatory molecules
necessary for T cell activation. DC-based tumor vaccines are
being explored as tumor immunotherapy. One approach
involves the introduction of tumor-associated antigens or
genes that are subsequently taken up by native DCs, which
then migrate to the draining lymph node. An alternative
strategy involves the administration of DCs manipulated ex
vivo to express tumor antigens [3-7].
DCs isolated from cancer patients exhibit quantitative and
functional deficiencies [8-11]. Decreased numbers of mature
DCs have been demonstrated in the tumor bed, draining
lymph nodes, and circulation in multiple tumor models. In
patients with head and neck squamous cell carcinoma
(HNSCC), numbers of DCs were halved in early-stage
patients, with a further decrease in patients with more
advanced disease [10]. DC subset analysis in patients with
breast cancer and HNSCC has revealed that decreases in
cell numbers are confined to DCs of the myeloid in
comparison with those of the plasmacytoid or lymphoid
lineage. Surgical debulking of breast and prostate cancer
results in a corresponding increase in myeloid-derived DCs
[10,12]. Minimal DCs are recruited to the tumor bed in
patients with renal and prostate cancer. Those present have
low levels of costimulatory molecules and a decreased
capacity to stimulate allogeneic T cell proliferation [11,13].
Similarly, DCs isolated from patients with colon cancer lack
expression of CD80 or CD86. In vitro culture with
granulocyte/macrophage colony-stimulating factor (GM-CSF)
and CD40 ligand (CD40L) or tumor necrosis factor (TNF) did
not result in the upregulation of costimulatory molecule
expression, suggesting that tumor cells cripple the capacity
of DCs to undergo normal differentiation [14]. In concert with
these findings is the relative predominance of immature DCs
in cancer patients that potentially induced tolerance by
presenting tumor antigens in the absence of costimulatory
signals.
In their study, Pinzon-Charry et al. [15] demonstrate that
circulating DCs isolated from early-stage breast cancer have
higher rates of spontaneous apoptosis than those from
healthy controls. Whereas previous studies have demon-
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strated that tumor cells induce apoptosis of blood DCs in
vitro, this report suggests that the reduction in circulating DC
populations arises from their increased rate of clearance in
vivo. The authors argue that this phenomenon results in a lack
of effective antigen presentation and contributes to a
permissive environment for tumor growth. They demonstrate
that a soluble factor contained in supernatant derived from
cultured breast cancer cell lines induces DC apoptosis.
Pinzon-Charry et al. show that 24-hour culture with tumor-
derived supernatant caused an increase in Lin–HLA-DR+
apoptotic cells as in comparison with DCs cultured with
peripheral blood mononuclear cell (PBMC)-derived
supernatant, supporting the authors’ hypothesis that tumor
products were responsible for the elevated proportions of
apoptotic blood DCs in the patients with breast cancer. A
variety of tumor-derived factors have been identified that
disrupt DC maturation and function, including IL-10 and
vascular endothelial growth factor [16,17]. IL-10, for example,
irreversibly blocks DC differentiation and induces CD4 and
CD8+ T cells that suppress antigen-specific responses [17].
It has been shown that IL-12 enhances the function of DCs
and promotes the differentiation and maturation of DCs
indirectly by the production of proinflammatory cytokines
such as interferon-γ, TNF-α, IL-6 and GM-CSF [18]. DCs
express IL-12 receptors, and their occupation initiates the
nuclear localization of members of the NF-κB family of
transcription factors [19]. IL-12 has also been reported to be
an anti-apoptotic factor for DCs, and a lack of production of
IL-12 by DCs may lead to early cell death. Pinzon-Charry et
al. demonstrate that incubation of DCs with CD40L was
protective against tumor-associated apoptosis. CD40 ligation
induced a modest increase in TNF-α and more marked
increases in IL-12 production. Culture with IL-12 alone also
reversed the pro-apoptotic effects of tumor supernatant. It is
noteworthy that exposure to tumor supernatant resulted in a
downregulation of Bcl-2 expression, which was reversed by
preincubation with IL-12 or CD40L. IL-12 has been reported
to protect in vitro derived DCs from apoptosis in prostate
cancer [20]. In contrast, IL-12 did not prevent tumor-
associated apoptosis when added to PBMCs during early
DC development.
Significance for immunotherapy
The findings presented by Pinzon-Charry et al. [15] help to
further define the immunologic milieu that fosters tumor immune
tolerance and carry important implications for the design of
immunotherapeutic strategies. The increased susceptibility of
blood DCs to apoptosis may result in a diminished capacity
to respond to tumor vaccines that depend on in vivo antigen
loading of native DCs. One strategy to circumvent this
limitation is through the use of DCs generated ex vivo that
are loaded with tumor antigens. Another strategy involves the
administration of adjuvant cytokines such as IL-12 to reverse
the tumor-associated inhibition of DCs. IL-12 has been
shown to augment the efficacy of cancer vaccines. IL-12
enhances the response to vaccination with DC/tumor fusions
in animal models and clinical studies [21].
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